Literature DB >> 18026579

Congenital cholestatic syndromes: what happens when children grow up?

S C Ling1.   

Abstract

Although advances in the management of children with congenital cholestasis have enabled many to survive into adulthood with their native livers, even the most common of these conditions remains rare in adult hepatology practice. Among four congenital cholestatic syndromes (biliary atresia, Alagille syndrome, Caroli disease and congenital hepatic fibrosis, and progressive familial intrahepatic cholestasis), the published data on outcomes of the syndromes into adulthood suggest that a spectrum of severity of liver disease can be expected, from cirrhosis (almost universal in adults with biliary atresia who have not required liver transplantation) to mild and subclinical (eg, in the previously undiagnosed affected parent of an infant with Alagille syndrome). Complications associated with portal hypertension and nutritional deficiencies are common, and other associated features of the cholestatic syndrome may require appropriate attention, such as congenital heart disease in Alagille syndrome. Indications for liver transplantation include synthetic failure, progressive encephalopathy, intractable pruritus, recurrent biliary sepsis and recurrent complications of portal hypertension. Improved understanding of biliary physiology will hopefully translate into improved therapy for children and adults with cholestasis.

Entities:  

Mesh:

Year:  2007        PMID: 18026579      PMCID: PMC2658590          DOI: 10.1155/2007/581247

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  68 in total

1.  Hepatocellular carcinoma in children with Alagille syndrome.

Authors:  Vivek A Bhadri; Michael O Stormon; Susan Arbuckle; Albert H Lam; Kevin J Gaskin; Albert Shun
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-11       Impact factor: 2.839

Review 2.  The hepatic fibrocystic diseases.

Authors:  Nanda Kerkar; Karen Norton; Frederick J Suchy
Journal:  Clin Liver Dis       Date:  2006-02       Impact factor: 6.126

Review 3.  Should children with esophageal varices receive beta-blockers for the primary prevention of variceal hemorrhage?

Authors:  Simon C Ling
Journal:  Can J Gastroenterol       Date:  2005-11       Impact factor: 3.522

4.  Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation.

Authors:  Elizabeth C Utterson; Ross W Shepherd; Ronald J Sokol; John Bucuvalas; John C Magee; Susan V McDiarmid; Ravinder Anand
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

5.  Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.

Authors:  Christiane Pauli-Magnus; Thomas Lang; Yvonne Meier; Tina Zodan-Marin; Diana Jung; Christian Breymann; Roland Zimmermann; Silke Kenngott; Ulrich Beuers; Christoph Reichel; Reinhold Kerb; Anja Penger; Peter J Meier; Gerd A Kullak-Ublick
Journal:  Pharmacogenetics       Date:  2004-02

6.  Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia.

Authors:  Dong-Yi Zhang; Gregg Sabla; Pranavkumar Shivakumar; Greg Tiao; Ronald J Sokol; Cara Mack; Benjamin L Shneider; Bruce Aronow; Jorge A Bezerra
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

7.  Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Virginia Moyer; Deborah K Freese; Peter F Whitington; Alan D Olson; Fred Brewer; Richard B Colletti; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-08       Impact factor: 2.839

8.  BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Christiane Pauli-Magnus; Reinhold Kerb; Karin Fattinger; Thomas Lang; Birgit Anwald; Gerd A Kullak-Ublick; Ulrich Beuers; Peter J Meier
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

Review 9.  Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality.

Authors:  Binita M Kamath; Nancy B Spinner; Karan M Emerick; Albert E Chudley; Carol Booth; David A Piccoli; Ian D Krantz
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

10.  Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11.

Authors:  Saskia W C van Mil; Wendy L van der Woerd; Gerda van der Brugge; Ekkehard Sturm; Peter L M Jansen; Laura N Bull; Inge E T van den Berg; Ruud Berger; Roderick H J Houwen; Leo W J Klomp
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

View more
  5 in total

1.  Successfully treated intractable pruritus with rifampin in a case of benign recurrent intrahepatic cholestasis.

Authors:  Teru Kumagi; E Jenny Heathcote
Journal:  Clin J Gastroenterol       Date:  2008-09-26

Review 2.  Biliary disease in children.

Authors:  Matthew Goldman; Thomas Pranikoff
Journal:  Curr Gastroenterol Rep       Date:  2011-04

3.  Prevalence of hypoglycemia among patients presenting with cholestasis of infancy in a nigerian teaching hospital.

Authors:  Alphonsus N Onyiriuka; Kayode A Adeniran; Eucharia P A Onyiriuka
Journal:  Oman Med J       Date:  2012-07

4.  Clinical Applicability of Whole-Exome Sequencing Exemplified by a Study in Young Adults with the Advanced Cryptogenic Cholestatic Liver Diseases.

Authors:  Maria Kulecka; Andrzej Habior; Agnieszka Paziewska; Krzysztof Goryca; Michalina Dąbrowska; Filip Ambrozkiewicz; Bożena Walewska-Zielecka; Andrzej Gabriel; Michal Mikula; Jerzy Ostrowski
Journal:  Gastroenterol Res Pract       Date:  2017-05-24       Impact factor: 2.260

5.  Paucity of intrahepatic bile ducts in neonates: the first case series from iran.

Authors:  Zahmatkeshan Mozhgan; Geramizadeh Bita; Haghighat Mahmood; Enteshari Hajar
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.